Target Name: WDR17
NCBI ID: G116966
Review Report on WDR17 Target / Biomarker Content of Review Report on WDR17 Target / Biomarker
WDR17
Other Name(s): WDR17 variant 2 | WD repeat-containing protein 17 (isoform 2) | WDR17_HUMAN | WD repeat-containing protein 17 | WD repeat domain 17, transcript variant 1 | WD repeat-containing protein 17 (isoform 1) | WDR17 variant 1 | WD repeat domain 17 | epididymis secretory sperm binding protein | WD repeat domain 17, transcript variant 2

WDR17: A Potential Drug Target for Cancer

WDR17 (WDR17 variant 2) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. WDR17 is a key regulator of the X chromosome gene expression and has been shown to play a role in the development and progression of several diseases, including cancer.

The WDR17 gene was first identified in the human genome in 2008 and has since been shown to encode a protein that is involved in the regulation of gene expression and has been implicated in the development and progression of several diseases, including cancer. The WDR17 protein is composed of 194 amino acid residues and has been shown to play a role in the regulation of X chromosome gene expression, specifically in the context of the X chromosome imprinted (XI) region.

WDR17 has been shown to be involved in the regulation of several key genes that are involved in the development and progression of cancer. For example, studies have shown that WDR17 is involved in the regulation of the expression of the tumor suppressor gene TP53, which is often mutated in cancer and plays a critical role in the development and progression of cancer.

In addition to its role in the regulation of TP53, WDR17 has also been shown to be involved in the regulation of the expression of several other genes that are involved in the development and progression of cancer. For example, studies have shown that WDR17 is involved in the regulation of the expression of the oncogene PDGFRA, which is often mutated in cancer and plays a critical role in the development and progression of cancer.

WDR17 has also been shown to be involved in the regulation of cell signaling pathways that are involved in the development and progression of cancer. For example, studies have shown that WDR17 is involved in the regulation of the signaling pathway associated with the TGF-β receptor , which is often mutated in cancer and plays a critical role in the development and progression of cancer.

In addition to its role in the regulation of gene expression, WDR17 has also been shown to play a role in the regulation of protein stability and translation efficiency. Studies have shown that WDR17 is involved in the regulation of the stability and translation efficiency of the X Chromosomal gene expression regulator, which is often mutated in cancer and plays a critical role in the development and progression of cancer.

WDR17 has also been shown to be involved in the regulation of cellular processes that are involved in the development and progression of cancer. For example, studies have shown that WDR17 is involved in the regulation of cell cycle progression, which is often mutated in cancer and plays a critical role in the development and progression of cancer.

In conclusion, WDR17 is a non-coding RNA molecule that has been shown to play a role in the development and progression of several diseases, including cancer. The WDR17 protein is composed of 194 amino acid residues and has been shown to play a role in the regulation of X chromosome gene expression, specifically in the context of the X chromosome imprinted (XI) region. Further research is needed to fully understand the role of WDR17 in the development and progression of cancer and to identify potential drug targets or biomarkers for this disease.

Protein Name: WD Repeat Domain 17

The "WDR17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16